AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA ...Middle East

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone...

Hence then, the article about amgen provides statement on maritide phase 1 data was published today ( Wednesday 13/11/2024 - 01:05 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA )

Also on site :

• Cyberattack hits Canvas system used by thousands of schools as finals loom
• Philadelphia Soccer 2026 otvára akreditácie médií a registráciu fanúšikov na festival fanúšikov FIFA Fan Festival™ vo Philadelphii
• China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients